Published in J Biol Chem on February 25, 2000
Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J (2001) 9.40
O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc Natl Acad Sci U S A (2004) 2.67
Mechanisms of tau-induced neurodegeneration. Acta Neuropathol (2009) 2.27
Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci (2007) 2.24
Structure of a protein phosphatase 2A holoenzyme: insights into B55-mediated Tau dephosphorylation. Mol Cell (2008) 1.93
The generation of a 17 kDa neurotoxic fragment: an alternative mechanism by which tau mediates beta-amyloid-induced neurodegeneration. J Neurosci (2005) 1.72
Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Curr Med Chem (2008) 1.64
Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. Am J Pathol (2003) 1.64
The role of tau in neurodegeneration. Mol Neurodegener (2009) 1.54
A TRPV channel in Drosophila motor neurons regulates presynaptic resting Ca2+ levels, synapse growth, and synaptic transmission. Neuron (2014) 1.52
Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease. Brain (2009) 1.48
Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome. FASEB J (2008) 1.43
Acceleration and persistence of neurofibrillary pathology in a mouse model of tauopathy following anesthesia. FASEB J (2009) 1.40
Up-regulation of inhibitors of protein phosphatase-2A in Alzheimer's disease. Am J Pathol (2005) 1.37
The in vivo neuromodulatory effects of the herbal medicine ginkgo biloba. Proc Natl Acad Sci U S A (2001) 1.27
Propofol directly increases tau phosphorylation. PLoS One (2011) 1.25
Activation of the ERK and JNK signaling pathways caused by neuron-specific inhibition of PP2A in transgenic mice. Am J Pathol (2003) 1.24
Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation. Br J Pharmacol (2007) 1.21
Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: Implication for Alzheimer's disease. Am J Pathol (2009) 1.21
Evidence for a fragile X mental retardation protein-mediated translational switch in metabotropic glutamate receptor-triggered Arc translation and long-term depression. J Neurosci (2012) 1.21
Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention. J Cell Mol Med (2007) 1.21
The excitotoxin quinolinic acid induces tau phosphorylation in human neurons. PLoS One (2009) 1.15
Tau and neurodegenerative disease: the story so far. Nat Rev Neurol (2015) 1.10
Okadaic-acid-induced inhibition of protein phosphatase 2A produces activation of mitogen-activated protein kinases ERK1/2, MEK1/2, and p70 S6, similar to that in Alzheimer's disease. Am J Pathol (2003) 1.10
Retracted Decrease in age-related tau hyperphosphorylation and cognitive improvement following vitamin D supplementation are associated with modulation of brain energy metabolism and redox state. Neuroscience (2014) 1.08
Therapeutic strategies for tau mediated neurodegeneration. J Neurol Neurosurg Psychiatry (2012) 1.07
Progression of tau pathology in cholinergic Basal forebrain neurons in mild cognitive impairment and Alzheimer's disease. Am J Pathol (2011) 1.07
Regulation between O-GlcNAcylation and phosphorylation of neurofilament-M and their dysregulation in Alzheimer disease. FASEB J (2007) 1.04
The carboxy-terminal fragment of inhibitor-2 of protein phosphatase-2A induces Alzheimer disease pathology and cognitive impairment. FASEB J (2010) 1.02
An experimental rat model of sporadic Alzheimer's disease and rescue of cognitive impairment with a neurotrophic peptide. Acta Neuropathol (2011) 1.02
Inhibition of JNK by a peptide inhibitor reduces traumatic brain injury-induced tauopathy in transgenic mice. J Neuropathol Exp Neurol (2012) 1.02
Glutamate system, amyloid ß peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology. J Psychiatry Neurosci (2013) 0.99
Dysregulation of protein phosphorylation/dephosphorylation in Alzheimer's disease: a therapeutic target. J Biomed Biotechnol (2006) 0.96
Neurofilamentopathy in neurodegenerative diseases. Open Neurol J (2011) 0.96
I1PP2A affects tau phosphorylation via association with the catalytic subunit of protein phosphatase 2A. J Biol Chem (2008) 0.95
Solution structure of the kinase-associated domain 1 of mouse microtubule-associated protein/microtubule affinity-regulating kinase 3. Protein Sci (2006) 0.94
Dysregulation of tau phosphorylation in mouse brain during excitotoxic damage. J Alzheimers Dis (2009) 0.92
N-glycosylation status of E-cadherin controls cytoskeletal dynamics through the organization of distinct β-catenin- and γ-catenin-containing AJs. Cell Health Cytoskelet (2009) 0.91
Synemin promotes AKT-dependent glioblastoma cell proliferation by antagonizing PP2A. Mol Biol Cell (2012) 0.90
SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination. Proc Natl Acad Sci U S A (2014) 0.90
Decrease of protein phosphatase 2A and its association with accumulation and hyperphosphorylation of tau in Down syndrome. J Alzheimers Dis (2008) 0.90
Alzheimer disease therapeutics: focus on the disease and not just plaques and tangles. Biochem Pharmacol (2014) 0.90
Early growth response 1 (Egr-1) regulates phosphorylation of microtubule-associated protein tau in mammalian brain. J Biol Chem (2011) 0.89
Activation of protein phosphatase 2B and hyperphosphorylation of Tau in Alzheimer's disease. J Alzheimers Dis (2011) 0.88
Developing pharmacological therapies for Alzheimer disease. Cell Mol Life Sci (2007) 0.87
Okadaic acid induces tau phosphorylation in SH-SY5Y cells in an estrogen-preventable manner. Brain Res (2010) 0.87
Declining phosphatases underlie aging-related hyperphosphorylation of neurofilaments. Neurobiol Aging (2009) 0.87
PP2B isolated from human brain preferentially dephosphorylates Ser-262 and Ser-396 of the Alzheimer disease abnormally hyperphosphorylated tau. J Neural Transm (Vienna) (2005) 0.87
From chronic cerebral hypoperfusion to Alzheimer-like brain pathology and neurodegeneration. Cell Mol Neurobiol (2014) 0.86
How does angiotensin AT(2) receptor activation help neuronal differentiation and improve neuronal pathological situations? Front Endocrinol (Lausanne) (2012) 0.85
Basis for MAP4 dephosphorylation-related microtubule network densification in pressure overload cardiac hypertrophy. J Biol Chem (2010) 0.84
Alzheimer disease and amyotrophic lateral sclerosis: an etiopathogenic connection. Acta Neuropathol (2013) 0.84
Lipopolysaccharide-induced tau phosphorylation and kinase activity--modulation, but not mediation, by corticotropin-releasing factor receptors. Eur J Neurosci (2011) 0.84
Ferulic acid attenuates the injury-induced decrease of protein phosphatase 2A subunit B in ischemic brain injury. PLoS One (2013) 0.83
Cytoskeletal role in protection of the failing heart by β-adrenergic blockade. Am J Physiol Heart Circ Physiol (2011) 0.82
The marine natural-derived inhibitors of glycogen synthase kinase-3beta phenylmethylene hydantoins: In vitro and in vivo activities and pharmacophore modeling. Bioorg Med Chem (2009) 0.82
The Beta-amyloid protein of Alzheimer's disease: communication breakdown by modifying the neuronal cytoskeleton. Int J Alzheimers Dis (2013) 0.82
Tau-tubulin kinase. Front Mol Neurosci (2014) 0.81
Focal Cerebral Ischemia Reduces Protein Phosphatase 2A Subunit B Expression in Brain Tissue and HT22 Cells. Lab Anim Res (2011) 0.81
Neurodegeneration behind bars: from molecules to jurisprudence. Front Psychiatry (2014) 0.81
Tau Hyperphosphorylation and Oxidative Stress, a Critical Vicious Circle in Neurodegenerative Tauopathies? Oxid Med Cell Longev (2015) 0.80
Yeast as a model system to study tau biology. Int J Alzheimers Dis (2011) 0.80
Roles of tau protein in health and disease. Acta Neuropathol (2017) 0.80
Therapeutic benefits of a component of coffee in a rat model of Alzheimer's disease. Neurobiol Aging (2014) 0.79
Identification of differentially expressed genes in SHSY5Y cells exposed to okadaic acid by suppression subtractive hybridization. BMC Genomics (2012) 0.79
Toxic tau oligomer formation blocked by capping of cysteine residues with 1,2-dihydroxybenzene groups. Nat Commun (2015) 0.79
Effect of Pin1 or microtubule binding on dephosphorylation of FTDP-17 mutant Tau. J Biol Chem (2009) 0.79
Lithium inhibits stress-induced changes in tau phosphorylation in the mouse hippocampus. J Neural Transm (Vienna) (2006) 0.78
Cytoplasmic SET induces tau hyperphosphorylation through a decrease of methylated phosphatase 2A. BMC Neurosci (2014) 0.78
A Novel Mechanism of Spine Damages in Stroke via DAPK1 and Tau. Cereb Cortex (2015) 0.78
TDP-43 suppresses tau expression via promoting its mRNA instability. Nucleic Acids Res (2017) 0.78
O-GlcNAcylation of protein kinase A catalytic subunits enhances its activity: a mechanism linked to learning and memory deficits in Alzheimer's disease. Aging Cell (2016) 0.77
Carboxyl terminus of heat-shock cognate 70-interacting protein degrades tau regardless its phosphorylation status without affecting the spatial memory of the rats. J Neural Transm (Vienna) (2008) 0.77
Liver-specific deletion of Ppp2cα enhances glucose metabolism and insulin sensitivity. Aging (Albany NY) (2015) 0.77
Neuronal degeneration, synaptic defects, and behavioral abnormalities in tau₄₅₋₂₃₀ transgenic mice. Neuroscience (2014) 0.77
Silencing [Formula: see text] Rescues Tau Pathologies and Memory Deficits through Rescuing PP2A and Inhibiting GSK-3β Signaling in Human Tau Transgenic Mice. Front Aging Neurosci (2014) 0.77
The tau code. Front Aging Neurosci (2009) 0.76
Memantine Attenuates Alzheimer's Disease-Like Pathology and Cognitive Impairment. PLoS One (2015) 0.76
Attenuation of okadaic acid-induced hyperphosphorylation of cytoskeletal proteins by heat preconditioning and its possible underlying mechanisms. Cell Stress Chaperones (2004) 0.76
Hypothermic Preconditioning Reverses Tau Ontogenesis in Human Cortical Neurons and is Mimicked by Protein Phosphatase 2A Inhibition. EBioMedicine (2015) 0.76
Tau physiology and pathomechanisms in frontotemporal lobar degeneration. J Neurochem (2016) 0.76
Is tau a suitable therapeutical target in tauopathies? World J Biol Chem (2010) 0.76
Curcumin treatment recovery the decrease of protein phosphatase 2A subunit B induced by focal cerebral ischemia in Sprague-Dawley rats. Lab Anim Res (2015) 0.76
Systematic Analysis of the Multiple Bioactivities of Green Tea through a Network Pharmacology Approach. Evid Based Complement Alternat Med (2014) 0.75
Dysregulation of protein phosphatase 2A in parkinson disease and dementia with lewy bodies. Ann Clin Transl Neurol (2016) 0.75
A new coumarin derivative, IMM-H004, attenuates okadaic acid-induced spatial memory impairment in rats. Acta Pharmacol Sin (2016) 0.75
Preclinical Metabolism, Pharmacokinetics and In Vivo Analysis of New Blood-Brain-Barrier Penetrant Fingolimod Analogues: FTY720-C2 and FTY720-Mitoxy. PLoS One (2016) 0.75
Early glycogen synthase kinase-3β and protein phosphatase 2A independent tau dephosphorylation during global brain ischaemia and reperfusion following cardiac arrest and the role of the adenosine monophosphate kinase pathway. Eur J Neurosci (2016) 0.75
Expression of Tau Pathology-Related Proteins in Different Brain Regions: A Molecular Basis of Tau Pathogenesis. Front Aging Neurosci (2017) 0.75
α-Lipoic acid improves abnormal behavior by mitigation of oxidative stress, inflammation, ferroptosis, and tauopathy in P301S Tau transgenic mice. Redox Biol (2017) 0.75
Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A (1986) 10.13
Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem (1986) 6.91
Abnormal fibrils from scrapie-infected brain. Acta Neuropathol (1981) 5.35
The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease. Neuroscience (2000) 3.40
Occurrence of neuropil threads in the senile human brain and in Alzheimer's disease: a third location of paired helical filaments outside of neurofibrillary tangles and neuritic plaques. Neurosci Lett (1986) 3.36
Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease. Brain Res (1989) 3.10
Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci U S A (2001) 2.97
Alzheimer paired helical filaments: bulk isolation, solubility, and protein composition. Acta Neuropathol (1984) 2.97
Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology (1999) 2.74
Alzheimer paired helical filaments: immunochemical identification of polypeptides. Acta Neuropathol (1984) 2.70
Alzheimer neurofibrillary tangles: monoclonal antibodies to inherent antigen(s). Acta Neuropathol (1984) 2.58
Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med (1996) 2.46
Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci U S A (1994) 2.39
Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J Biol Chem (1993) 2.30
Ultrastructural morphology of amyloid fibrils from neuritic and amyloid plaques. Acta Neuropathol (1983) 2.23
Evidence that Alzheimer neurofibrillary tangles originate from neurotubules. Lancet (1979) 2.22
Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol (1999) 2.08
Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res (2010) 2.07
Phosphoprotein phosphatase activities in Alzheimer disease brain. J Neurochem (1993) 2.05
Brain levels of microtubule-associated protein tau are elevated in Alzheimer's disease: a radioimmuno-slot-blot assay for nanograms of the protein. J Neurochem (1992) 2.04
Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch Biochem Biophys (1993) 1.90
Defective brain microtubule assembly in Alzheimer's disease. Lancet (1986) 1.89
MRI of entorhinal cortex in mild Alzheimer's disease. Lancet (1999) 1.86
Ultrastructure of paired helical filaments of Alzheimer's neurofibrillary tangle. J Neuropathol Exp Neurol (1984) 1.86
Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain. J Neurochem (1995) 1.86
Ultrastructural studies of the cells forming amyloid fibers in classical plaques. Can J Neurol Sci (1989) 1.84
Post-translational modifications of tau protein in Alzheimer's disease. J Neural Transm (Vienna) (2004) 1.78
Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. Proc Natl Acad Sci U S A (1997) 1.73
Ultrastructure of the microglia that phagocytose amyloid and the microglia that produce beta-amyloid fibrils. Acta Neuropathol (1992) 1.71
Relationships between regional neuronal loss and neurofibrillary changes in the hippocampal formation and duration and severity of Alzheimer disease. J Neuropathol Exp Neurol (1997) 1.67
Protein changes in senile dementia. Brain Res (1974) 1.65
Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Curr Med Chem (2008) 1.64
Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J Neuropathol Exp Neurol (1997) 1.63
Glycosylation of microtubule-associated protein tau: an abnormal posttranslational modification in Alzheimer's disease. Nat Med (1996) 1.57
Role of feedforward control of movement stability in reducing slip-related balance loss and falls among older adults. J Neurophysiol (2003) 1.52
Simulated movement termination for balance recovery: can movement strategies be sought to maintain stability in the presence of slipping or forced sliding? J Biomech (1999) 1.52
Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int (2006) 1.52
Microtubule-associated polypeptides tau are altered in Alzheimer paired helical filaments. Brain Res (1988) 1.51
An antigenic profile of Lewy bodies: immunocytochemical indication for protein phosphorylation and ubiquitination. J Neuropathol Exp Neurol (1989) 1.51
Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules. Arch Biochem Biophys (1998) 1.51
Lewy bodies contain epitopes both shared and distinct from Alzheimer neurofibrillary tangles. J Neuropathol Exp Neurol (1988) 1.49
Ferritin is a component of the neuritic (senile) plaque in Alzheimer dementia. Acta Neuropathol (1990) 1.43
Amyloid protein and neurofibrillary tangles coexist in the same neuron in Alzheimer disease. Proc Natl Acad Sci U S A (1989) 1.40
Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ. Acta Neuropathol (1995) 1.40
Alzheimer neurofibrillary tangles: antiserum and immunohistological staining. Ann Neurol (1979) 1.39
Ultrastructural studies of the cells forming amyloid in the cortical vessel wall in Alzheimer's disease. Acta Neuropathol (1992) 1.39
Glutamine synthetase in muscle and kidney. Biochem J (1970) 1.38
Cell surface immunoglobulin. VII. Synthesis, shedding, and secretion of immunoglobulin by lymphoid cells of germ-free mice. J Exp Med (1974) 1.38
Alzheimer paired helical filaments: cross-reacting polypeptide/s normally present in brain. Acta Neuropathol (1985) 1.36
Neurofibrillary tangles in Alzheimer's disease and progressive supranuclear palsy: antigenic similarities and differences. Microtubule-associated protein tau antigenicity is prominent in all types of tangles. Acta Neuropathol (1987) 1.35
Hippocampal atrophy in early Alzheimer's disease: anatomic specificity and validation. Psychiatr Q (1993) 1.33
Tau is phosphorylated by GSK-3 at several sites found in Alzheimer disease and its biological activity markedly inhibited only after it is prephosphorylated by A-kinase. FEBS Lett (1998) 1.33
Dephosphorylation of Alzheimer paired helical filaments by protein phosphatase-2A and -2B. J Biol Chem (1995) 1.32
Factors associated with poor outcomes in patients with lupus nephritis. Lupus (2005) 1.30
Neurofibrillary pathology--correlation with hippocampal formation atrophy in Alzheimer disease. Neurobiol Aging (1997) 1.30
Restoration of biological activity of Alzheimer abnormally phosphorylated tau by dephosphorylation with protein phosphatase-2A, -2B and -1. Brain Res Mol Brain Res (1996) 1.30
Identification and localization of a tau peptide to paired helical filaments of Alzheimer disease. Proc Natl Acad Sci U S A (1989) 1.29
Interaction of tau isoforms with Alzheimer's disease abnormally hyperphosphorylated tau and in vitro phosphorylation into the disease-like protein. J Biol Chem (2001) 1.28
Levels of normal and abnormally phosphorylated tau in different cellular and regional compartments of Alzheimer disease and control brains. FEBS Lett (1994) 1.27
Alzheimer paired helical filaments: identification of polypeptides with monoclonal antibodies. Acta Neuropathol (1985) 1.27
Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J Neural Transm Park Dis Dement Sect (1990) 1.27
Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration. Brain Res (1998) 1.23
Histopathological criteria for progressive dementia disorders: clinical-pathological correlation and classification by multivariate data analysis. Acta Neuropathol (1987) 1.22
Chemical relationship of the paired helical filaments of Alzheimer's dementia to normal human neurofilaments and neurotubules. Brain Res (1978) 1.21
Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention. J Cell Mol Med (2007) 1.21